Abstract
Nerve growth factor (NGF) has long been known for its effects on neuronal cell survival and differentiation. This prototypical neurotrophic factor stimulates neurons through two distinct classes of membrane receptors: the TrkA tyrosine kinase receptor, and the tumor necrosis factor receptor family member p75NTR, also known as the common neurotrophin receptor. Somewhat surprisingly, there is a growing body of evidence indicating that NGF is also a major stimulator of breast cancer cell growth. Both the survival and proliferation of breast cancer cells are strongly stimulated by NGF, mediated by TrkA and p75NTR respectively, utilising signaling pathways similar to those described for neurons. In addition, although NGF is produced by breast cancer cells, it is not in normal breast epithelial cells, giving rise to an autocrine stimulation of tumor growth. Therefore, NGF receptors and signaling are thus looking increasingly promising as potential drug targets for breast cancer.
Keywords: breast cancer, nerve growth factor, receptors and signaling, therapeutic target
Current Cancer Drug Targets
Title: Nerve Growth Factor Receptors and Signaling in Breast Cancer
Volume: 4 Issue: 6
Author(s): Laurent Dolle, Eric Adriaenssens, Ikram El Yazidi-Belkoura, Xuefen Le Bourhis, Victor Nurcombe and Hubert Hondermarck
Affiliation:
Keywords: breast cancer, nerve growth factor, receptors and signaling, therapeutic target
Abstract: Nerve growth factor (NGF) has long been known for its effects on neuronal cell survival and differentiation. This prototypical neurotrophic factor stimulates neurons through two distinct classes of membrane receptors: the TrkA tyrosine kinase receptor, and the tumor necrosis factor receptor family member p75NTR, also known as the common neurotrophin receptor. Somewhat surprisingly, there is a growing body of evidence indicating that NGF is also a major stimulator of breast cancer cell growth. Both the survival and proliferation of breast cancer cells are strongly stimulated by NGF, mediated by TrkA and p75NTR respectively, utilising signaling pathways similar to those described for neurons. In addition, although NGF is produced by breast cancer cells, it is not in normal breast epithelial cells, giving rise to an autocrine stimulation of tumor growth. Therefore, NGF receptors and signaling are thus looking increasingly promising as potential drug targets for breast cancer.
Export Options
About this article
Cite this article as:
Dolle Laurent, Adriaenssens Eric, Yazidi-Belkoura El Ikram, Bourhis Le Xuefen, Nurcombe Victor and Hondermarck Hubert, Nerve Growth Factor Receptors and Signaling in Breast Cancer, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332853
DOI https://dx.doi.org/10.2174/1568009043332853 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies
Current Pharmaceutical Design Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Developmental Expression of the Translocator Protein 18 kDa (TSPO) in Testicular Germ Cells
Current Molecular Medicine Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines
Current Neuropharmacology Gut Inflammation in Response to Injury: Potential Target for Therapeutic Intervention
Recent Patents on Anti-Infective Drug Discovery An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Editorial (Thematic Issue: "Discovery and Development of New Anticancer Drugs Inspired from Natural Product Leads" Part 1)
Anti-Cancer Agents in Medicinal Chemistry The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Formulation and Stability Aspects of Nanosized Solid Drug Delivery Systems
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Medicinal Chemistry Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets